SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing significant discussion and extreme volatility after Novo Nordisk filed a patent infringement lawsuit over its compounded semaglutide products, which Hims has since ceased, with the community sharply divided between concerns over legal and regulatory risks and the belief that the stock is oversold with short-squeeze potential.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending due to a striking disconnect between recent strong earnings, profitability, and a $500M share buyback, and an unprecedented streak of red daily candles pushing the stock to historic lows. Community sentiment is fiercely divided on whether this presents a generational buying opportunity fueled by its AI/AR smartglasses vision and a potential short squeeze, or if persistent management issues will continue to suppress its value.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending after issuing weaker-than-expected revenue guidance for the current quarter and fiscal year, despite a strong earnings beat, intensifying investor concerns that AI is disrupting the traditional software business model. The community is sharply divided, with many viewing the steep selloff as an overreaction and a buying opportunity given the company's cash position, while others remain cautious about AI's long-term impact on the SaaS sector.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl is trending after a sharp stock drop driven by a deteriorated financial outlook, unexpected leadership changes, a delayed filing, and an SEC probe into its accounting practices, leading to a community split between those seeing an oversold buying opportunity and others fearing significant financial irregularities.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending following its all-stock acquisition of Valaris, a $5.8 billion deal set to create a combined $17 billion offshore drilling industry leader. The community is actively discussing the potential for a strengthened fleet and significant cost savings to capitalize on an emerging upcycle, though some express concerns over shareholder dilution.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending down sharply after its mixed Q4 earnings report, featuring a revenue miss and conservative forward guidance. This has ignited intense community debate over whether the fintech stock is now severely undervalued and a buying opportunity, or if the market is overreacting amidst broader sector weakness.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio (RGNX) is trending due to a clinical hold placed on its RGX-121 and RGX-111 gene therapy programs following a potential tumor link with the AAV vector, just days before RGX-121's critical PDUFA date. The community is intensely debating whether an imminent Complete Response Letter or a delay is inevitable, with many expecting significant downside, while others highlight the company's other pipeline assets as the true value drivers.

Tokenized asset from Ondo Finance representing BigBear.ai Holdings (Ondo Tokenized).

BigBear.ai Holdings (Ondo Tokenized Stocks)

BigBear.ai Holdings (Ondo Tokenized Stocks) is trending as the community actively discovers and discusses this tokenized asset, prompting questions about its existence, the broader implications of such financial instruments, and its potential relationship to the underlying NYSE-listed BBAI stock.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following an 'Overweight' initiation and bullish price target from Morgan Stanley, amplifying the narrative around its strategic pivot to AI and high-performance computing data centers. The community is actively discussing the company's strong power infrastructure and key partnerships, like Google, positioning it favorably amidst booming demand for computing capacity, despite some noting its historical correlation with Bitcoin prices.

Valaris Ltd. engages in the provision of offshore contract drilling services to the international oil and gas industry. It operates through the following segments: Floaters, Jackups, ARO, and Other. The Floaters segment includes drillships and semisubmersible rigs. The Other segment is involved in management services on rigs owned by third-parties and the activities associated with arrangements with ARO under the bareboat charter arrangements. The company was founded in 1975 and is headquartered in Hamilton, Bermuda.

Valaris Ltd

Valaris is trending following the announcement of its all-stock acquisition by Transocean for approximately $5.8 billion, leading to significant community discussion around the deal's implications for shareholders and warrants. This M&A activity coincides with Valaris securing substantial new drilling contracts and ongoing conversations about a strengthening offshore energy sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Prelude Therapeutics now anticipates dosing the first patient with PRT12396 by the second quarter of 2026.</li><li>The early stage trial will determine the safety, efficacy and pharmacokinetic profile of PRT12396.</li><li>The company said that the FDA’s clearance marks the first milestone in its focus on certain programs that it outlined in the last quarter.</li></ul> Shares of Prelude Therapeutics Incorporated (PRLD) closed 13% higher on Tuesday and edged up 2% after hours after the U.S. Food and Drug Administration (FDA) gave clearances to proceed with early-stage trials for its experimental drug PRT12396.PRT12396 is being developed for the treatment of patients with certain myeloproliferative neoplasms. Myeloproliferative neoplasms (MPNs) are a group of rare, slow-growing blood cancers where the bone marrow produces too many red blood cells, platelets, or certain white blood cells, often due to acquired genetic mutations, leading to symptoms like fatigue, itching, headaches, and bleeding or clotting issues.<h2 class="st-heading-2">Trial Design And Timeline</h2>Prelude Therapeutics <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/03/3231175/0/en/Prelude-Therapeutics-Receives-FDA-Clearance-of-Investigational-New-Drug-Application-IND-for-PRT12396-a-Mutant-selective-JAK2V617F-Inhibitor.html">anticipates</a> dosing the first patient with the drug by the second quarter of 2026. The company said that the FDA’s clearance marks the first milestone in its focus on certain programs that it outlined in the last quarter.“We look forward to advancing PRT12396 into the phase 1 study in patients with polycythemia vera and myelofibrosis in parallel,” said Kris Vaddi, Chief Executive Officer of Prelude. Both polycythemia vera and myelofibrosis are types of blood cancer.The early-stage trial will determine the safety, efficacy and pharmacokinetic profile of PRT12396.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PRLD stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.A Stocktwits user opined that the news might be a hint that the company is moving in the right direction.<stembedurl>https://www.stocktwits.com/Jaybird827/message/643826772</stembedurl>Another voiced optimism for the stock rising as high as $3.<stembedurl>https://www.stocktwits.com/moosegoose/message/643791216</stembedurl><a href="https://stocktwits.com/symbol/PRLD">PRLD stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-shares-garner-retail-attention-ahead-of-q4-earnings-report/cZb02YuR4mN">VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did PRLD Stock Surge 13% Today?

Prelude Therapeutics said on Tuesday that the FDA gave clearances to proceed with early-stage trials for its experimental drug PRT12396. 

Equity

Prelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Hold at Wall Street Zen

Wall Street Zen cut Prelude Therapeutics from a "buy" rating to a "hold" rating in a research note on Sunday...

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 28.5% in December

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest...

Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 2.1% - What's Next?

Prelude Therapeutics (NASDAQ:PRLD) Trading 2.1% Higher - Time to Buy...

Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus

GS stands out as Zacks showcases how its stock picks like MU and PRLD delivered strong gains despite a shaky market.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

Prelude Therapeutics (NASDAQ:PRLD) Issues Earnings Results

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.26) earnings per share for the quarter, topping the consensus...

Prelude Therapeutics Inc Q3 Loss Decreases, Beats Estimates

(RTTNews) - Prelude Therapeutics Inc (PRLD) revealed Loss for third quarter that decreased from the same period last year and beat the Street estimates...

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated (Prelude or the Company...

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Prelude Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

PRLD
Prelude Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PRLD News

PRLDPrelude Therapeutics Inc